December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Akoya BioSciences, Inc. - Common Stock (NQ:AKYA)

1.290 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akoya BioSciences, Inc. - Common Stock

< Previous 1 2 3 Next >
Akoya Biosciences Reports First Quarter 2025 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
From Kahn Swick & Foti, LLC
Via Business Wire
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
From Quanterix Corporation
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PPBI, SSBK, AKYA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pacific Premier Bancorp, Inc. (Nasdaq - PPBI), Southern States Bancshares, Inc. (Nasdaq - SSBK), Akoya Biosciences, Inc. (Nasdaq - AKYA)
From Brodsky & Smith LLC
Via GlobeNewswire
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
ADC assay now available through ABS; customer study proves IO60 is a spatial workhorse 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
From Akoya Biosciences, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AKYA, CKPT, QTRX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
From Akoya Biosciences, Inc.
Via GlobeNewswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
From Kahn Swick & Foti, LLC
Via Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Akoya Biosciences, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
From Quanterix Corporation
Via Business Wire
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma... 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports Third Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports Second Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Reports First Quarter 2024 Financial Results
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing... 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
From Akoya Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.